| Simbrinza (U.S.N.L.M.) | |
|---|---|
| Dosing | 1 drop tid |
| Chem Specs | brinzolamide 1% / brimonidine 0.2% |
| Quantities | 8ml |
| Cost | 216.82 |
| Class | CAI / selective α 2 receptor agonist |
| Action | CAI's slow the formation of bicarbonate with subsequent reduction in sodium and fluid transport. Brimonidine reduces aqueous production and increases uveoscleral outflow. |
| Usage | Indicated for the reduction of elevated IOP in open-angle glaucoma or ocular hypertension. |
| First line therapy for patients unable to use PGA's. Also shown (in Alcon supported study) to be an effective adjunct to PGA therapy. |
|
| Contraindications | Hypersensitivity to any ingredients in the product. |
| Warnings | Systemic absorption of sulfonamides (Brinzolamide) can lead to severe adverse reactions, e.g. epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, etc. Be alert for sensitisation from readministration. Brimonidine may potentiate effects associated with vascular insufficiency. |
| Pediatric use | Contraindicated in children under the age of 2 |
| Pregnancy | Category C.Rabbit maternal toxicity at 120x normal human dose. Slight increase in fetal variations at 20x. |
| Tachyphylaxis and allergic responses less common with Brimonidine than Apraclonidine. 0.003% BAK |